MEPs on the special committee to oversee lessons learned from the Covid-19 pandemic wanted, on Monday 10 October, to question the heads of Pfizer and CureVac, in particular about the development of vaccines and past and potential contracts between their companies and the Commission.
Franz-Werner Haas represented CureVac. The majority of MEPs deplored the absence of Albert Bourla, CEO ofPfizer (see EUROPE B13039A13).
“Mr Bourla is not here, I’m sorry: I know that his presence could have...